Manuscripts

Search by keyword, year, or author name.

Showing 1572 manuscripts.

Human b-defensin-3 activates professional antigen-presenting cells via toll-like receptors 1 and 2

Nicholas T. Funderburg, Michael M. Lederman, Zhimin Feng, Michael G. Drage, Julie Jadlowsky, Clifford V. Harding, Scott F. Sieg. Human b-defensin-3 activates professional antigen-presenting cells via toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 2007. 104: 18631-5.

Year

2007

Journal

Proceedings of the National Academy of Sciences of the United States of America

Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration

Edward R. Cachay, Niousha Moini, Sergei L. Kosakovsky Pond, Rick L. Pesano, Yolanda Lie, Heidi Aiem, David M. Butler, Scott L. Letendre, W. Christopher Mathews, Davey M. Smith. Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. The Open AIDS Journal. 2007. 1: 5-10.

Year

2007

Journal

The Open AIDS Journal

Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis

Susan L Rosenkranz, Kevin E. Yarasheski, Michael F. Para, Richard C. Reichman, Gene D. Morse. Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis. Metabolic Syndrome and Related Disorders. 2007. 5: 163-73.

Year

2007

Journal

Metabolic Syndrome and Related Disorders

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

Carmen D. Zorrilla, Russell B. Van Dyke, Arlene D. Bardeguez, Edward P. Acosta, Elizabeth (Betsy) Smith, Michael Hughes, Sharon Huang, Heather D. Watts, Barbara E. Heckman, Barbara E. Heckman, Eleanor Jimenez, George D. McSherry, Lynne M. Mofenson. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.. Antimicrobial Agents and Chemotherapy. 2007. 51: 2208 - 2210. PMID: 17420209

Year

2007

Journal

Antimicrobial Agents and Chemotherapy

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s)

Pablo Tebas, Jiameng Zhang, Kevin E. Yarasheski, Scott Evans, Margaret A. Fischl, Abby Helen Shevitz, Judith Feinberg, Ann C. Collier, Cecilia M. Shikuma, Barbara Brizz, Fred Richard Sattler. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of Acquired Immune Deficiency Syndromes. 2007. 45: 193-200.

Year

2007

Journal

Journal of Acquired Immune Deficiency Syndromes

Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis

Nancy Radcliffe Reynolds, Junfeng Sun, Haikady N. Nagaraja, Allen L. Gifford, Albert W. Wu, Margaret A. Chesney. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. Journal of Acquired Immune Deficiency Syndromes. 2007. 46: 402-9.

Year

2007

Journal

Journal of Acquired Immune Deficiency Syndromes

Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211

Daniel R. Kuritzkes, Roy (Trip) Gulick, Zhaohui Su, Charles Flexner, Michael Hughes, Paul Skolnik, Timothy J. Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew R. Zolopa, Richard C. Reichman, Catherine Godfrey, Martin S. Hirsch. Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases. 2007. 196: 304-12.

Year

2007

Journal

Journal of Infectious Diseases